Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-12-08 00:00:00 ET · period of report 2022-12-06 · accession 0001209191-22-060339 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-08 | 2022-12-06 | VRTX | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +12.8K | 58.0K | +28% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-06 | A | A | 12,753 | $0.00 | 58,031 | D | — | — | (F1) Restricted stock unit award that vests on 07/01/2025. |